Smad4 is required to inhibit osteoclastogenesis and maintain bone mass

Mayu Morita, Shigeyuki Yoshida, Ryotaro Iwasaki, Tetsuro Yasui, Yuiko Sato, Tami Kobayashi, Ryuichi Watanabe, Takatsugu Oike, Kana Miyamoto, Masamichi Takami, Keiko Ozato, Chu Xia Deng, Hiroyuki Aburatani, Sakae Tanaka, Akihiko Yoshimura, Yoshiaki Toyama, Morio Matsumoto, Masaya Nakamura, Hiromasa Kawana, Taneaki NakagawaTakeshi Miyamoto

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Bone homeostasis is maintained as a delicate balance between bone-resorption and bone-formation, which are coupled to maintain appropriate bone mass. A critical question is how bone-resorption is terminated to allow bone-formation to occur. Here, we show that TGFβs inhibit osteoclastogenesis and maintain bone-mass through Smad4 activity in osteoclasts. We found that latent-TGFβ1 was activated by osteoclasts to inhibit osteoclastogenesis. Osteoclast-specific Smad4 conditional knockout mice (Smad4-cKO) exhibited significantly reduced bone-mass and elevated osteoclast formation relative to controls. TGFβ1-activation induced expression of Irf8 and Bcl6, both of which encode factors inhibiting osteoclastogenesis, by blocking their negative regulator, Prdm1, in osteoclasts in a Smad4-dependent manner. Reduced bone-mass and accelerated osteoclastogenesis seen in Smad4-cKO were abrogated by Prdm1 deletion. Administration of latent-TGFβ1-Fc to wild-type mice antagonized LPS-induced bone destruction in a model of activated osteoclast-mediated bone destruction. Thus, latent-TGFβ1-Fc could serve as a promising new therapeutic agent in bone diseases marked by excessive resorption.

Original languageEnglish
Article number35221
JournalScientific Reports
Volume6
DOIs
Publication statusPublished - 2016 Oct 12

Fingerprint

Osteogenesis
Osteoclasts
Bone and Bones
Bone Resorption
Knockout Mice
Bone Diseases
Homeostasis

ASJC Scopus subject areas

  • General

Cite this

Morita, M., Yoshida, S., Iwasaki, R., Yasui, T., Sato, Y., Kobayashi, T., ... Miyamoto, T. (2016). Smad4 is required to inhibit osteoclastogenesis and maintain bone mass. Scientific Reports, 6, [35221]. https://doi.org/10.1038/srep35221

Smad4 is required to inhibit osteoclastogenesis and maintain bone mass. / Morita, Mayu; Yoshida, Shigeyuki; Iwasaki, Ryotaro; Yasui, Tetsuro; Sato, Yuiko; Kobayashi, Tami; Watanabe, Ryuichi; Oike, Takatsugu; Miyamoto, Kana; Takami, Masamichi; Ozato, Keiko; Deng, Chu Xia; Aburatani, Hiroyuki; Tanaka, Sakae; Yoshimura, Akihiko; Toyama, Yoshiaki; Matsumoto, Morio; Nakamura, Masaya; Kawana, Hiromasa; Nakagawa, Taneaki; Miyamoto, Takeshi.

In: Scientific Reports, Vol. 6, 35221, 12.10.2016.

Research output: Contribution to journalArticle

Morita, M, Yoshida, S, Iwasaki, R, Yasui, T, Sato, Y, Kobayashi, T, Watanabe, R, Oike, T, Miyamoto, K, Takami, M, Ozato, K, Deng, CX, Aburatani, H, Tanaka, S, Yoshimura, A, Toyama, Y, Matsumoto, M, Nakamura, M, Kawana, H, Nakagawa, T & Miyamoto, T 2016, 'Smad4 is required to inhibit osteoclastogenesis and maintain bone mass', Scientific Reports, vol. 6, 35221. https://doi.org/10.1038/srep35221
Morita M, Yoshida S, Iwasaki R, Yasui T, Sato Y, Kobayashi T et al. Smad4 is required to inhibit osteoclastogenesis and maintain bone mass. Scientific Reports. 2016 Oct 12;6. 35221. https://doi.org/10.1038/srep35221
Morita, Mayu ; Yoshida, Shigeyuki ; Iwasaki, Ryotaro ; Yasui, Tetsuro ; Sato, Yuiko ; Kobayashi, Tami ; Watanabe, Ryuichi ; Oike, Takatsugu ; Miyamoto, Kana ; Takami, Masamichi ; Ozato, Keiko ; Deng, Chu Xia ; Aburatani, Hiroyuki ; Tanaka, Sakae ; Yoshimura, Akihiko ; Toyama, Yoshiaki ; Matsumoto, Morio ; Nakamura, Masaya ; Kawana, Hiromasa ; Nakagawa, Taneaki ; Miyamoto, Takeshi. / Smad4 is required to inhibit osteoclastogenesis and maintain bone mass. In: Scientific Reports. 2016 ; Vol. 6.
@article{bda939d5dce0475d98147df517af2749,
title = "Smad4 is required to inhibit osteoclastogenesis and maintain bone mass",
abstract = "Bone homeostasis is maintained as a delicate balance between bone-resorption and bone-formation, which are coupled to maintain appropriate bone mass. A critical question is how bone-resorption is terminated to allow bone-formation to occur. Here, we show that TGFβs inhibit osteoclastogenesis and maintain bone-mass through Smad4 activity in osteoclasts. We found that latent-TGFβ1 was activated by osteoclasts to inhibit osteoclastogenesis. Osteoclast-specific Smad4 conditional knockout mice (Smad4-cKO) exhibited significantly reduced bone-mass and elevated osteoclast formation relative to controls. TGFβ1-activation induced expression of Irf8 and Bcl6, both of which encode factors inhibiting osteoclastogenesis, by blocking their negative regulator, Prdm1, in osteoclasts in a Smad4-dependent manner. Reduced bone-mass and accelerated osteoclastogenesis seen in Smad4-cKO were abrogated by Prdm1 deletion. Administration of latent-TGFβ1-Fc to wild-type mice antagonized LPS-induced bone destruction in a model of activated osteoclast-mediated bone destruction. Thus, latent-TGFβ1-Fc could serve as a promising new therapeutic agent in bone diseases marked by excessive resorption.",
author = "Mayu Morita and Shigeyuki Yoshida and Ryotaro Iwasaki and Tetsuro Yasui and Yuiko Sato and Tami Kobayashi and Ryuichi Watanabe and Takatsugu Oike and Kana Miyamoto and Masamichi Takami and Keiko Ozato and Deng, {Chu Xia} and Hiroyuki Aburatani and Sakae Tanaka and Akihiko Yoshimura and Yoshiaki Toyama and Morio Matsumoto and Masaya Nakamura and Hiromasa Kawana and Taneaki Nakagawa and Takeshi Miyamoto",
year = "2016",
month = "10",
day = "12",
doi = "10.1038/srep35221",
language = "English",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Smad4 is required to inhibit osteoclastogenesis and maintain bone mass

AU - Morita, Mayu

AU - Yoshida, Shigeyuki

AU - Iwasaki, Ryotaro

AU - Yasui, Tetsuro

AU - Sato, Yuiko

AU - Kobayashi, Tami

AU - Watanabe, Ryuichi

AU - Oike, Takatsugu

AU - Miyamoto, Kana

AU - Takami, Masamichi

AU - Ozato, Keiko

AU - Deng, Chu Xia

AU - Aburatani, Hiroyuki

AU - Tanaka, Sakae

AU - Yoshimura, Akihiko

AU - Toyama, Yoshiaki

AU - Matsumoto, Morio

AU - Nakamura, Masaya

AU - Kawana, Hiromasa

AU - Nakagawa, Taneaki

AU - Miyamoto, Takeshi

PY - 2016/10/12

Y1 - 2016/10/12

N2 - Bone homeostasis is maintained as a delicate balance between bone-resorption and bone-formation, which are coupled to maintain appropriate bone mass. A critical question is how bone-resorption is terminated to allow bone-formation to occur. Here, we show that TGFβs inhibit osteoclastogenesis and maintain bone-mass through Smad4 activity in osteoclasts. We found that latent-TGFβ1 was activated by osteoclasts to inhibit osteoclastogenesis. Osteoclast-specific Smad4 conditional knockout mice (Smad4-cKO) exhibited significantly reduced bone-mass and elevated osteoclast formation relative to controls. TGFβ1-activation induced expression of Irf8 and Bcl6, both of which encode factors inhibiting osteoclastogenesis, by blocking their negative regulator, Prdm1, in osteoclasts in a Smad4-dependent manner. Reduced bone-mass and accelerated osteoclastogenesis seen in Smad4-cKO were abrogated by Prdm1 deletion. Administration of latent-TGFβ1-Fc to wild-type mice antagonized LPS-induced bone destruction in a model of activated osteoclast-mediated bone destruction. Thus, latent-TGFβ1-Fc could serve as a promising new therapeutic agent in bone diseases marked by excessive resorption.

AB - Bone homeostasis is maintained as a delicate balance between bone-resorption and bone-formation, which are coupled to maintain appropriate bone mass. A critical question is how bone-resorption is terminated to allow bone-formation to occur. Here, we show that TGFβs inhibit osteoclastogenesis and maintain bone-mass through Smad4 activity in osteoclasts. We found that latent-TGFβ1 was activated by osteoclasts to inhibit osteoclastogenesis. Osteoclast-specific Smad4 conditional knockout mice (Smad4-cKO) exhibited significantly reduced bone-mass and elevated osteoclast formation relative to controls. TGFβ1-activation induced expression of Irf8 and Bcl6, both of which encode factors inhibiting osteoclastogenesis, by blocking their negative regulator, Prdm1, in osteoclasts in a Smad4-dependent manner. Reduced bone-mass and accelerated osteoclastogenesis seen in Smad4-cKO were abrogated by Prdm1 deletion. Administration of latent-TGFβ1-Fc to wild-type mice antagonized LPS-induced bone destruction in a model of activated osteoclast-mediated bone destruction. Thus, latent-TGFβ1-Fc could serve as a promising new therapeutic agent in bone diseases marked by excessive resorption.

UR - http://www.scopus.com/inward/record.url?scp=84991107774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991107774&partnerID=8YFLogxK

U2 - 10.1038/srep35221

DO - 10.1038/srep35221

M3 - Article

C2 - 27731422

AN - SCOPUS:84991107774

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 35221

ER -